Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,409 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-04-24 English
Regulatory Filings 2024
Regulatory Filings
2024-04-24 English
Communiqué de presse : L’étude de phase III LUNA 3 du rilzabrutinib pour le traitement de la thrombocytopénie immune a atteint son critère d’évaluation primaire
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces positive Phase III study results (LUNA 3) for a drug (rilzabrutinib) for treating immune thrombocytopenia (ITP). It explicitly mentions upcoming regulatory submissions ("Soumissions réglementaires prévues aux États-Unis et dans l'Union européenne d'ici à la fin de l'année") and provides key clinical data highlights, management commentary, and details about the study design. This structure—announcing key results immediately followed by context and future plans—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical milestones. Since it focuses on the *release* of clinical trial results and future regulatory steps, and is not a full, comprehensive periodic report (like 10-K or IR), it aligns best with the 'Earnings Release' category (ER), which often encompasses major operational/clinical announcements outside of standard financial reporting periods, or the general 'Regulatory Filings' (RNS) if ER is too narrow. Given the focus on clinical trial success and upcoming submissions, it functions as a major corporate announcement. However, 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a clinical/pipeline announcement, not a financial results announcement. Therefore, the most appropriate general category for a significant, non-standard corporate announcement that doesn't fit other specific categories (like M&A, DIV, etc.) is the fallback, Regulatory Filings (RNS), as it is a formal communication to the market about a material event. It is not a Call Transcript (CT), Investor Presentation (IP), or a full report (AR, IR).
2024-04-23 French
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Earnings Release Classification · 99% confidence The document is explicitly titled 'Press Release' and announces positive Phase 3 study results ('LUNA 3 study met primary endpoint') for a drug candidate (Rilzabrutinib) and outlines future regulatory submission timelines ('Regulatory submissions in the US and EU anticipated by year-end'). This format—a concise announcement of key results and future plans, often including boilerplate about the company and forward-looking statements—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/pipeline news. Since the definitions provided include 'Earnings Release (Code: ER)' for the 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this document is a press release announcing clinical trial success (a major corporate event often released alongside or instead of quarterly financials), ER is the most appropriate fit among the choices, as it represents a high-level, immediate announcement of performance/progress highlights. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). FY 2024
2024-04-23 English
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and details positive Phase II clinical trial results for a drug candidate (frexalimab) in treating multiple sclerosis. It includes scientific data, quotes from researchers and management, and contact information for media and investors. This format is characteristic of an initial announcement of significant company news, often preceding a full financial report or presentation. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Investor Presentation (IP). Since it is an initial release of key results, the most appropriate classification is Earnings Release (ER), as this category often encompasses major operational or clinical milestones announced via press release, even if not strictly quarterly earnings figures. It is not a Report Publication Announcement (RPA) because it contains the substantive information itself, not just a notice that a report is available.
2024-04-17 French
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and contains key highlights, clinical data updates (48-week phase 2 data for frexalimab), quotes from management/investigators, and contact information for Media and Investor Relations. This structure is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on presenting new clinical trial results and supporting data rather than summarizing overall quarterly financial performance (which would be an ER or IR), and it is not a full regulatory report (like 10-K or IR), it fits best as a general announcement of significant corporate/scientific news. However, among the provided options, the content is most closely aligned with the initial announcement of results, which often overlaps with an Earnings Release (ER) if it were quarterly results, or a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on scientific data presentation and the format being a 'Press Release' announcing data that will be presented at a conference, it functions as a high-level summary of new information. Since it is not a formal financial report (10-K, IR) or a simple announcement of a report's publication (RPA), and it contains substantial new information, 'ER' is often used for major announcements, but 'RNS' (Regulatory Filings/General Announcement) is a safer fit for non-standard financial disclosures like clinical trial updates presented via press release, especially when the content is scientific rather than purely financial performance metrics. Given the options, and recognizing this is a press release announcing scientific progress rather than a mandatory financial filing or a report itself, RNS is the most appropriate general category for significant, non-standard corporate news releases.
2024-04-17 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.